OBJECTIVES The aim of this study was to assess the safety of the concurrent administration of a clopidogrel and prasugrel loading dose in patients undergoing primary percutaneous coronary intervention.
undergoing primary coronary intervention (PCI) to complement optimal epicardial and myocardial reperfusion while protecting against recurrent ischemic events (1). The administration of a clopidogrel loading dose before primary PCI has been shown to reduce ischemic events, with a 600-mg loading dose emerging as the preferred regimen (2, 3) . Compared with clopidogrel, prasugrel provides a more rapid onset and more potent and consistent inhibition of platelet aggregation (4, 5) . In STEMI patients undergoing PCI, prasugrel has been shown to be more effective than clopidogrel by reducing the risk of cardiovascular mortality, myocardial infarction, and stroke as well as stent thrombosis (6) . Of note, improved efficacy in STEMI patients was not associated with an increased risk of bleeding throughout 15 months of follow-up. Recent guidelines for the management of STEMI patients recommend prasugrel over clopidogrel in patients undergoing primary PCI, without commenting on the use of prasugrel in clopidogrel pre-treated patients (7, 8) . Clopidogrel, however, is frequently administered upstream, even in STEMI patients. The administration of a prasugrel loading dose in patients already exposed to clopidogrel has raised concerns about bleeding and potential drug interactions, thereby potentially offsetting beneficial effects in terms of efficacy. We therefore assessed the safety and efficacy of 2 loading regimens consisting of clopidogrel and a subsequent prasugrel loading dose and a prasugrel loading dose alone using pre-specified endpoint definitions for safety and efficacy with assessment of adverse events by an independent adjudication committee in a large, contemporary population of STEMI patients undergoing primary PCI. Because no effect of a concomitant loading dose of clopidogrel and prasugrel is expected during the maintenance period of the therapy, the endpoints were assessed at hospital discharge and at 30 days. The SPUM-ACS cohort study is a multicenter, observational cohort study of patients presenting with acute coronary syndrome (ACS) conducted at 4 Swiss university hospitals (in Bern, Geneva, Lausanne, and Zurich). Inclusion criteria were the presence of an ACS and age older than 18 years. Exclusion criteria comprised severe physical disability, inability to comprehend study, and life expectancy <1 year. bleeding (which were history of coronary artery Table 1 . Patients receiving clopidogrel and a subsequent loading dose of prasugrel tended to be older and less frequently had dyslipidemia and renal failure. Procedural characteristics are shown in Table 2 . The baseline TIMI flow tended to be improved in patients receiving clopidogrel and a subsequent prasugrel loading dose, and the average stent diameter was smaller in the group receiving clopidogrel and a subsequent loading dose of prasugrel.
LOADING DOSE REGIMEN. Medications before, during, or immediately after the primary PCI, at the time of hospital discharge, at 30 days, and at 1-year followup are summarized in Table 3 , including details regarding loading and maintenance doses. Bivalirudin and glycoprotein IIb/IIIa were less frequently Values are mean AE SD or n (%). *p values pairwise (prasugrel þ clopidogrel vs. prasugrel alone) from chi-square, Fisher exact, Student t test, or Mann-Whitney U test. †Anemia was defined as a hemoglobin concentration <120 g/l for women and <130 g/l for men, according to the definition of the World Health Organization. ‡Thrombocytopenia was defined as <150,000 platelets/ml. §Left ventricular function as assessed by angiography at the time point of presentation or by echocardiography if angiography was not available. kLong lesion indicates any lesion treated with a summed stent length of $20 mm. Table 5) . Similarly, no differences in TIMI major (1.2% vs. 1.8%) or TIMI minor (0.7% vs. 1.6%), and GUSTO severe (0.5% vs.
1.3%) or GUSTO moderate (0.5% vs. 0.5%) bleeding episodes were observed at 30 days (Table 5) , and there were no differences in terms of bleeding localization ( Table 6) 
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DISCUSSION
We report the results of the largest retrospective cohort study of prospectively collected data in- Values are n (%) unless otherwise indicated. Incidence rate ratios (95% confidence interval CI) and p values from Poisson regressions (crude analyses) or Poisson regressions weighted by the inverse probability of treatment weighted and adjusted for study (COMFORTABLE or BIOMARKER), insulin-dependent diabetes, history of coronary artery bypass grafting, anemia, thrombocytopenia, Killip III or IV, left ventricular ejection fraction after 10 times multiple imputation of missing values using chained equations (adjusted analyses). Risk ratio with continuity correction and Fisher exact test p values are reported, in case of zero events in one treatment group. The inverse probability of treatment weighted was calculated using the following baseline variables: age, sex, diabetes, hypercholesterolemia, current smoker, family history of coronary artery disease, previous coronary artery bypass grafting, pain onset within 24 h, acute myocardial infarction location, stent type, and procedural medications including unfractionated heparin, bivalirudin, low molecular weight heparin, glycoprotein II/IIIa antagonists ST ¼ stent thrombosis; other abbreviations as in Tables 2 and 4 . prasugrel loading after a clopidogrel loading dose will result only in a minor difference in actual platelet inhibition.
Radial access is associated with a lower risk of access site bleeding in STEMI patients (23) . In the present study, only 2 centers preferentially used a radial access route, limited to 155 patients. When we performed a sensitivity analysis excluding the 2 centers preferentially using a radial access route, we found similar hazards of bleeding between groups.
In the present study, the dual-loading regimen of prasugrel and clopidogrel as well as loading with prasugrel alone were associated with a similar efficacy as 
